Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 3
2017 3
2018 2
2019 3
2020 3
2021 2
2022 1
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Führer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ; LIBRETTO-531 Trial Investigators. Hadoux J, et al. N Engl J Med. 2023 Nov 16;389(20):1851-1861. doi: 10.1056/NEJMoa2309719. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870969 Clinical Trial.
Kinase inhibitors in thyroid cancers.
Sukrithan V, Jain P, Shah MH, Konda B. Sukrithan V, et al. Endocr Oncol. 2023 Jan 13;3(1):e220062. doi: 10.1530/EO-22-0062. eCollection 2023 Jan 1. Endocr Oncol. 2023. PMID: 37434642 Free PMC article. Review.
Emerging drugs for the treatment of adrenocortical carcinoma.
Sukrithan V, Husain M, Kirschner L, Shah MH, Konda B. Sukrithan V, et al. Expert Opin Emerg Drugs. 2021 Jun;26(2):165-178. doi: 10.1080/14728214.2021.1920922. Epub 2021 May 3. Expert Opin Emerg Drugs. 2021. PMID: 33896321 Review.
Emerging drugs for EGFR-mutated non-small cell lung cancer.
Sukrithan V, Deng L, Barbaro A, Cheng H. Sukrithan V, et al. Expert Opin Emerg Drugs. 2019 Mar;24(1):5-16. doi: 10.1080/14728214.2018.1558203. Epub 2018 Dec 20. Expert Opin Emerg Drugs. 2019. PMID: 30570396 Review.
A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms.
Owen DH, Benner B, Wei L, Sukrithan V, Goyal A, Zhou Y, Pilcher C, Suffren SA, Christenson G, Curtis N, Jukich M, Schwarz E, Savardekar H, Norman R, Ferguson S, Kleiber B, Wesolowski R, Carson WE, Otterson GA, Verschraegen CF, Shah MH, Konda B. Owen DH, et al. Among authors: sukrithan v. Clin Cancer Res. 2023 Feb 16;29(4):731-741. doi: 10.1158/1078-0432.CCR-22-1552. Clin Cancer Res. 2023. PMID: 36255391 Free PMC article.
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors.
Abuzakhm SM, Sukrithan V, Fruth B, Qin R, Strosberg J, Hobday TJ, Semrad T, Reidy-Lagunes D, Kindler HL, Kim GP, Knox JJ, Kaubisch A, Villalona-Calero M, Chen H, Erlichman C, Shah MH. Abuzakhm SM, et al. Among authors: sukrithan v. Endocr Relat Cancer. 2023 Sep 13;30(11):e220301. doi: 10.1530/ERC-22-0301. Print 2023 Nov 1. Endocr Relat Cancer. 2023. PMID: 37702588 Free PMC article. Clinical Trial.
A systematic review finds limited data on measurement properties of instruments measuring outcomes in adult intensive care unit survivors.
Robinson KA, Davis WE, Dinglas VD, Mendez-Tellez PA, Rabiee A, Sukrithan V, Yalamanchilli R, Turnbull AE, Needham DM. Robinson KA, et al. Among authors: sukrithan v. J Clin Epidemiol. 2017 Feb;82:37-46. doi: 10.1016/j.jclinepi.2016.08.014. Epub 2016 Nov 16. J Clin Epidemiol. 2017. PMID: 27865899 Free PMC article. Review.
22 results